Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.Shaohua Li, Rong Guo, Yuan Cheng et al.|Journal of Clinical Oncology|2021Cited by 30
Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial.Wei Wei, Rongping Guo, Shaohua Li et al.|Journal of Clinical Oncology|2023Cited by 13
Postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX to improve outcomes of patients with hepatocellular carcinoma with microvascular invasion: A prospective multicenter, phase 3, randomized, controlled clinical trial.Shaohua Li, Rongping Guo, Jie Mei et al.|Journal of Clinical Oncology|2022Cited by 4